跳至主要内容
临床试验/CTRI/2025/11/098233
CTRI/2025/11/098233尚未招募不适用

A Prospective, Multicenter clinical trial to validate the diagnostic accuracy of Nerve Vue in detecting Peripheral Arterial Disease (PAD)

Aarca Research India Pvt. Ltd2 个研究点 分布在 1 个国家目标入组 500 人开始时间: 2025年12月29日最近更新:

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
500
试验地点
2
主要终点
Diagnostic Accuracy of NerveVue: The primary objective is to evaluate

研究概览

简要总结

The main purpose of this study is to evaluate whether Nerve Vue can accurately detect and monitor Peripheral Arterial Disease (PAD) in human subjects. Specifically, the study aims to determine if the device can identify early signs of compromised blood flow that are characteristic of PAD, thereby enabling proactive healthcare interventions and personalized care for at-risk individuals.

Background

Cardiovascular and metabolic health disorders remain major global health concerns, contributing to significant morbidity, mortality, and healthcare costs. Among these disorders, Peripheral Arterial Disease (PAD) is a particularly prevalent condition characterized by reduced blood flow to the limbs due to arterial narrowing or blockages. PAD often coexists with metabolic syndrome-an umbrella term encompassing risk factors such as obesity, insulin resistance, dyslipidaemia, and hypertension. When left unaddressed, PAD can lead to serious complications such as pain, limited mobility, and increased risk of cardiovascular events. Despite its prevalence, early detection of PAD remains challenging. Conventional diagnostic methods (e.g. Ankle-Brachial Index, Doppler ultrasound) are effective but can be time-intensive or require specialized equipment and expertise. This often results in underdiagnosis of PAD- especially among individuals with subclinical or mild disease. Consequently, there is a need for non-invasive, user-friendly technologies that enable earlier identification and monitoring of vascular compromise in diverse healthcare settings. In line with this need, the investigational device Nerve Vue integrates photoplethysmography (PPG) and piezoelectric sensors to capture and analyse peripheral pulse signals. By providing a rapid and comprehensive assessment of blood flow, Nerve Vue may allow healthcare professionals to identify early vascular changes indicative of PAD. This could ultimately facilitate proactive management strategies, mitigate progression, and improve overall vascular outcomes in affected individuals.

研究设计

研究类型
Interventional
分配方式
Na
盲法
None

入排标准

年龄范围
25.00 Year(s) 至 34.00 Year(s)(—)
性别
All

入选标准

  • Age greater than or equal to 35 years. or Age 25 to 34 years with one or more of the following risk factors:.
  • BMI greater than 25 kg/m².
  • Elevated waist circumference: greater than 35 inches for women and greater than 40 inches for men.
  • Habitually physically inactive (does not exercise regularly).
  • Has a first-degree relative with diabetes.
  • Ethnicity with elevated risk for type 2 diabetes.
  • Has delivered a baby weighing greater than 9 lb or was diagnosed with gestational diabetes.
  • Hypertension (greater than or equal to 130/greater than or equal to 85 mmHg) or being treated for hypertension.
  • HDL cholesterol level less than 35 mg/dL and/or a fasting triglyceride level greater than or equal to 250 mg/dL (or being treated for Dyslipidemia with medication).
  • Previously diagnosed with Polycystic Ovary Syndrome (PCOS).
  • Conditions associated with insulin resistance, such as acanthosis nigricans.
  • History of vascular disease including heart attack, stroke, angina, coronary heart disease, atherosclerosis, congestive heart failure, or peripheral arterial disease.

排除标准

  • Age under 25 years or.
  • Received investigational treatments in the past 14 days.
  • Presence of psychosocial issues that interfere with the ability to follow study procedures.
  • conditions that causes secondary diabetes including cushing syndrome, acromegaly, hemochromatosis, Pancreatitis, or cystic fibrosis.
  • Diagnosed with any type of diabetes, including type 1 or type
  • Taking glucose-lowering medications with the exception of metformin.
  • Known to be pregnant.
  • Receiving dialysis or having known renal compromise.
  • Scars, tattoos, rashes, or other disruptions/discolorations on the limbs or areas of sensor application that may interfere with proper usage of NerveVue.
  • Recent (within the past month) or current oral steroid therapy or chemotherapy, or chemotherapy within the past 12 months.
  • Receiving medications that fluoresce or known to have, or be at risk for, photosensitivity reactions (e.g., sensitive to ultraviolet light, or taking medication known to cause photosensitivity).

结局指标

主要结局

Diagnostic Accuracy of NerveVue: The primary objective is to evaluate

时间窗: There is only one visit, i,e Baseline /screening /Enrolment visit

NerveVue’s sensitivity and specificity in detecting early or subclinical Peripheral

时间窗: There is only one visit, i,e Baseline /screening /Enrolment visit

Arterial Disease (PAD). This includes comparing the device’s measurement

时间窗: There is only one visit, i,e Baseline /screening /Enrolment visit

outputs (e.g., pulse-wave indices, perfusion metrics) against established diagnostic

时间窗: There is only one visit, i,e Baseline /screening /Enrolment visit

standards, such as the Ankle-Brachial Index (ABI) and Doppler Ultrasound.

时间窗: There is only one visit, i,e Baseline /screening /Enrolment visit

次要结局

  • - Comparison with Standard Diagnostic Methods: A comparative analysis will be performed to assess the level of agreement between NerveVue results & existing PAD assessment techniques. Concordance, correlation coefficients, & potential advantages or limitations in various clinical environments will be documented.(- Usability & Acceptability: The study will collect structured feedback from both participants & clinical personnel on factors such as ease of use, comfort, setup time, & overall user satisfaction. These insights will inform potential device refinements & practical considerations for routine clinical use.)

研究者

发起方
Aarca Research India Pvt. Ltd
申办方类型
Other [Medical device manufacturing]
责任方
Principal Investigator
主要研究者

Gayathri Choda

Aarca Research India Pvt, Ltd

研究点 (2)

Loading locations...

相似试验